4.4 Letter

Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Letter Dermatology

Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than BRAFV600E mutations

Jiaosheng Xu et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Review Oncology

BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues

Ibrahim Halil Sahin et al.

Summary: BRAFV600E mutation is the most common oncogenic alteration in colorectal cancer, recent studies have found a combination therapy of BRAF and/or MEK inhibition with epidermal growth factor receptor-directed therapy to be effective for patients with BRAFV600-mutant colorectal cancer. Immune checkpoint inhibitor therapy is more appealing for patients with BRAFV600E-mutant mismatch repair-deficient colorectal cancer.

JCO ONCOLOGY PRACTICE (2021)

Review Oncology

Targeting Alterations in the RAF-MEK Pathway

Rona Yaeger et al.

CANCER DISCOVERY (2019)

Article Medicine, Research & Experimental

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients

Quan Lin et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

Article Oncology

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Eli L. Diamond et al.

CANCER DISCOVERY (2016)

Article Medicine, General & Internal

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Biochemistry & Molecular Biology

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Sonja J. Heidorn et al.

Review Oncology

Uncommon histiocytic disorders: The non-Langerhans cell histiocytoses

S Weitzman et al.

PEDIATRIC BLOOD & CANCER (2005)